Company / Depreciation & Amortization
Kura Oncology, Inc. Depreciation & Amortization History
FY2016-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Depreciation & Amortization
$849.0K
FY2023
5-year range
$558.0K / $849.0K
FY2019-FY2023
Trend
+11.9%
vs FY2022
Sector context
#128 of 168
Health Care
What the data says
Kura Oncology, Inc.'s depreciation & amortization of $849,000 is lower than 76% of companies in the Health Care sector (FY2023). Depreciation & Amortization has increased for 4 consecutive years, from $0 in FY2019 to $849,000 in FY2023.
Based on SEC 10-K filings.
$849,000 in FY2023 with a 5-year CAGR of +143.1%.
Increased from $558,000 to $849,000 over the past 2 years.
Health Care sector context is included.
Depreciation & Amortization over time
Growth rates
- 3-Year CAGR
- +63.6%
- 5-Year CAGR
- +143.1%
- 10-Year CAGR
- -
Sector benchmark
-99.6% below sector average
Key checks
Key Insights
- Kura Oncology, Inc.'s depreciation & amortization has grown for 3 consecutive years.
- 5-year CAGR of +143.1%, indicating consistent growth.
- In FY2023, depreciation & amortization increased 11.9% year-over-year.
- Ranks #128 out of 168 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -1.83 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Depreciation & AmortizationValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | $849.0K | +11.9% |
| FY2022 | $759.0K | +36.0% |
| FY2021 | $558.0K | +187.6% |
| FY2020 | $194.0K | - |
| FY2019 | $0 | -100.0% |
| FY2018 | $10.0K | -66.7% |
| FY2017 | $30.0K | -3.2% |
| FY2016 | $31.0K | +55.0% |
As of FY2023 · SEC 10-K · Updated Mar 28, 2026